Acumetis names Ramil Burden CEO as founder Brent Herspiegel joins board

By Public Technologies
  • DFW Capital Partners portfolio company Acumetis named Ramil Burden chief executive officer, effective Sept. 14, 2026.
  • Founder Brent Herspiegel stepped down as CEO, moved to the board to support the leadership transition.
  • Burden previously served as CEO of Optum Life Sciences, spent 17 years at GSK in senior commercial, strategy roles.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DFW Capital Partners LP published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.